Education
About Us
Working with TipRanks
Follow Us
BCAL Diagnostics Limited (AU:BDX)
ASX:BDX
Total Valuation
BCAL Diagnostics Limited has a market cap or net worth of AU$26.35M. The enterprise value is AU$20.91M.
Market CapAU$26.35M
Enterprise ValueAU$20.91M
Share Statistics
BCAL Diagnostics Limited has 365,967,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding365,967,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BCAL Diagnostics Limited’s return on equity (ROE) is -1.16 and return on invested capital (ROIC) is -73.79%.
Return on Equity (ROE)-1.16
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-73.79%
Return on Capital Employed (ROCE)-1.46
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BCAL Diagnostics Limited is ―. BCAL Diagnostics Limited’s PEG ratio is 0.14.
PE Ratio―
PS Ratio1047.06
PB Ratio3.64
Price to Fair Value3.64
Price to FCF-3.27
Price to Operating Cash Flow-4.08
PEG Ratio0.14
Income Statement
In the last 12 months, BCAL Diagnostics Limited had revenue of 21.64K and earned -7.24M in profits. Earnings per share was -0.02.
Revenue21.64K
Gross Profit21.64K
Operating Income-9.96M
Pretax Income-7.24M
Net Income-7.24M
EBITDA-6.19M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -6.14M and capital expenditures -787.67K, giving a free cash flow of -6.92M billion.
Operating Cash Flow-6.14M
Free Cash Flow-6.92M
Free Cash Flow per Share-0.02
Dividends & Yields
BCAL Diagnostics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change-46.15%
50-Day Moving Average0.06
200-Day Moving Average0.08
Relative Strength Index (RSI)54.11
Average Volume (3m)329.61K
Important Dates
BCAL Diagnostics Limited upcoming earnings date is Feb 25, 2026, Before Open (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
BCAL Diagnostics Limited as a current ratio of 2.32, with Debt / Equity ratio of 38.24%
Current Ratio2.32
Quick Ratio2.32
Debt to Market Cap0.07
Net Debt to EBITDA0.35
Interest Coverage Ratio-108.26
Taxes
In the past 12 months, BCAL Diagnostics Limited has paid -2.63M in taxes.
Income Tax-2.63M
Effective Tax Rate0.36
Enterprise Valuation
BCAL Diagnostics Limited EV to EBITDA ratio is -3.31, with an EV/FCF ratio of -2.96.
EV to Sales947.98
EV to EBITDA-3.31
EV to Free Cash Flow-2.96
EV to Operating Cash Flow-3.34
Balance Sheet
BCAL Diagnostics Limited has AU$4.52M in cash and marketable securities with AU$2.38M in debt, giving a net cash position of AU$2.14M billion.
Cash & Marketable SecuritiesAU$4.52M
Total DebtAU$2.38M
Net CashAU$2.14M
Net Cash Per Share<AU$0.01
Tangible Book Value Per ShareAU$0.02
Margins
Gross margin is 100.00%, with operating margin of -46043.03%, and net profit margin of -33465.98%.
Gross Margin100.00%
Operating Margin-46043.03%
Pretax Margin-33465.98%
Net Profit Margin-33465.98%
EBITDA Margin-28623.89%
EBIT Margin-33254.67%
Analyst Forecast
The average price target for BCAL Diagnostics Limited is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast23.85%